Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months
- PMID: 20028263
- DOI: 10.1089/jop.2009.0005
Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months
Abstract
Introduction: As glaucoma is one of the most significant causes of blindness, and administration of calcium channel blockers is effective in reducing intraocular pressure (IOP) in rabbits and patients with normotensive glaucoma, we administered topical verapamil 0.25% in the human eye to compare its effect with timolol 0.5% in reducing IOP.
Purpose: To compare the effect of timolol 0.5% and topical verapamil 0.25% in patients with open-angle glaucoma.
Methods: It was a double-blinded study in which 118 eyes (59 individuals) were chosen and divided into 2 groups (30 individuals related to timolol and 29 individuals related to verapamil). Patients who used drugs (systemic or topical) that could alter IOP and those with IOP <22 mmHg were excluded from the study (19 eyes). We chose patients who did not use any drugs 24 h prior to the study. Then applanation tonometry was done exactly before the administration of drugs and 90 min later and the results were compared.
Results: In timolol group, mean intraocular pressure in 52 eyes (27 right eyes and 25 left eyes) decreased from 32.545 to 30.230 and mean pressure in verapamil group decreased from 33.195 to 30.835.
Conclusion: It seems that topical verapamil has a similar effect to timolol in patients with open-angle glaucoma, so it can be considered as a lowering intraocular pressure agent in glaucoma patients.
Similar articles
-
Effect of Topical Calcium Channel Blockers on Intraocular Pressure in Steroid-induced Glaucoma.J Curr Glaucoma Pract. 2014 Jan-Apr;8(1):15-9. doi: 10.5005/jp-journals-10008-1155. Epub 2014 Jan 16. J Curr Glaucoma Pract. 2014. PMID: 26997802 Free PMC article. Review.
-
A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.Clin Ther. 2006 Mar;28(3):332-9. doi: 10.1016/j.clinthera.2006.03.001. Clin Ther. 2006. PMID: 16750448 Clinical Trial.
-
Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs.Vet Ophthalmol. 2006 Jul-Aug;9(4):245-9. doi: 10.1111/j.1463-5224.2006.00469.x. Vet Ophthalmol. 2006. PMID: 16771760 Clinical Trial.
-
The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.Ophthalmology. 2005 Mar;112(3):376-85. doi: 10.1016/j.ophtha.2004.10.034. Ophthalmology. 2005. PMID: 15745762 Clinical Trial.
-
Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series.Curr Drug Saf. 2018;13(1):3-11. doi: 10.2174/1574886312666171030125804. Curr Drug Saf. 2018. PMID: 29086700 Review.
Cited by
-
Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.J Ocul Pharmacol Ther. 2016 Dec;32(10):642-649. doi: 10.1089/jop.2016.0042. Epub 2016 Nov 11. J Ocul Pharmacol Ther. 2016. PMID: 27835065 Free PMC article.
-
Effect of Topical Calcium Channel Blockers on Intraocular Pressure in Steroid-induced Glaucoma.J Curr Glaucoma Pract. 2014 Jan-Apr;8(1):15-9. doi: 10.5005/jp-journals-10008-1155. Epub 2014 Jan 16. J Curr Glaucoma Pract. 2014. PMID: 26997802 Free PMC article. Review.
-
Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity.Br J Pharmacol. 2011 Sep;164(1):170-80. doi: 10.1111/j.1476-5381.2011.01336.x. Br J Pharmacol. 2011. PMID: 21434880 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials